In a controlled silicone kidney model, CVAC 2.0 outperformed a FANS sheath system for moderate-to-larger stone fragments across clearance efficiency, residual volume, and surgeon ergonomics, though the authors note the model was designed to isolate aspiration mechanics rather than replicate full clinical procedures.
Despite promising candidates across tumor, immune, and systemic marker categories, no biomarker yet reliably predicts BCG response or identifies which NMIBC patients would benefit from adding checkpoint inhibitor therapy—a gap that limits informed shared decision-making and broader adoption of IO-BCG combinations despite positive trial data.
Bogdana Schmidt, MD, MPH, identified several subgroups most likely to harbor occult systemic disease and therefore potentially benefit from adding immunotherapy to BCG:
Two new analyses from the ASPIRE trial showed lower health care consumption events and reduced follow-up costs with the SURE procedure vs URS, with RSV emerging as a key predictor of long-term utilization.
The PRIMARY2 phase 3 trial found that PSMA PET-CT in men with normal or equivocal MRI results safely halved the number of prostate biopsies, maintained non-inferior detection of clinically significant cancer, and reduced insignificant cancer diagnosis by more than half.
Sara Coca Membribes, MD, highlights several emerging therapeutic strategies with near-term clinical implications.
At EAU 2026, Adam B. Weiner, MD, spoke with Nikita Bhatt, MD, about the growing interest in prehabilitation to optimize patients ahead of cystectomy.
Enolen implants demonstrated minimal systemic drug exposure and early signals of tumor volume reduction in localized prostate cancer.
64Cu-SAR-bisPSMA demonstrated higher lesion detection rates, improved diagnostic accuracy, and a substantial impact on clinical management.
According to Chew, Break Wave lithotripsy is best suited to renal and ureterovesical junction stones, where ultrasound visualization is most reliable.
A subgroup analysis of the POTOMAC trial showed that durvalumab plus BCG I+M had consistent safety and efficacy in older patients with BCG-naïve high-risk NMIBC.
At 1 year, patients randomized to Rezūm showed a 4.6-point greater improvement on the IPSS symptom score compared with those escalated to combination therapy.
On actionable guidance for community practitioners, Kamat's most emphatic recommendation is early pathology review.
Antoni Vilaseca Cabo, MD, characterizes these results as proof of concept for the local delivery approach, with phase 2 and 3 trials now underway.
Guerrero-Ramos argues that landmark survival data from recent trials justify perioperative immunotherapy in muscle-invasive bladder cancer, while acknowledging that validated tools for individual patient selection remain elusive and that urologists must engage closely with medical oncology to deliver optimal care.
Final results from a phase 1 study of Erda-iDRS provide proof-of-concept for sustained local delivery of erdafitinib into the bladder.
On diagnostic pitfalls, Necchi highlights penile cancer as a particularly common source of delay.
Data showed that the addition of PSMA-PET/CT reduced the need for prostate biopsy by nearly half without compromising the detection of clinically significant prostate cancer.
On counseling patients who want to avoid cystectomy, Bogdana Schmidt, MD, MPH, points to trimodality therapy as the established bladder-preserving option, supported by longer-term data and propensity-matched analyses showing outcomes comparable to cystectomy in selected patients.
Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology.
Evangelia Sereti, MSc, PhD, discusses the design/methodology and results of a preclinical study exploring the combination of the PARP inhibitor olaparib plus the novel agent NOV202 in BRCA1/2-mutated prostate cancer cells.
“Clinicians should considerer these data when prescribing 5-ARIs to patients,” said Dr. Antonio Franco.
Prostate cancer screening with MRI-guided biopsy reduced the detection of clinically insignificant prostate cancer versus use of standard biopsy alone, while also demonstrating noninferiority for detecting clinically significant disease.
Adjuvant pembrolizumab reduced the risk of disease recurrence or death versus placebo in the phase 3 KEYNOTE-564 trial, but overall survival data are still immature.
“This is a completely new therapeutic concept; a precision medicine that delivers radiation directly to a high incidence tumor," said Ken Herrmann, MD.
Photodynamic diagnosis with blue light was associated with improved outcomes compared to white light cystoscopy in patients with bladder cancer who received TURBT.
Investigators report that high urinary cotinine levels are associated with a greater risk of recurrence in smokers.
With supporting data from larger series, using Ga-68 PSMA PET as a lymph node invasion prediction tool instead of nomograms could avoid unnecessary lymphadenectomies during radical prostatectomy,” said Yakup Kordan, MD.
The so-called “obesity paradox” previously reported in other genitourinary malignancies has now been observed in patients with metastatic castration-resistant prostate cancer.
